Suppr超能文献

肝细胞癌(HCC)肝切除术联合直接切除门静脉主干内的瘤栓。

Liver resection for hepatocellular carcinoma (HCC) with direct removal of tumor thrombi in the main portal vein.

作者信息

Yamaoka Y, Kumada K, Ino K, Takayasu T, Shimahara Y, Mori K, Tanaka A, Morimoto T, Taki Y, Washida M

机构信息

Second Department of Surgery, Kyoto University Faculty of Medicine, Japan.

出版信息

World J Surg. 1992 Nov-Dec;16(6):1172-6; discussion 1177. doi: 10.1007/BF02067093.

Abstract

Since the tumor thrombus in the main portal vein appears in the terminal stage of hepatocellular carcinoma (HCC), any attempt to remove it surgically is thought to be impractical as the malignancy itself cannot be entirely removed. During the past 5 years, we have performed tumor thrombectomy combined with hepatectomy in 29 of 298 patients with HCC. This combined therapy was initially decided upon as an emergency measure to prevent impending rupture of esophageal varices, rather than to improve patient survival. Since portal flow was obtained after removal of thrombi, this condition enabled transcatheter arterial embolization (TAE) and/or percutaneous ethanol injection therapy (PEIT). Although improved patient survival was not the primary goal of the emergency operation and there was an operative mortality of 11%, half of the other patients in the present series had unexpectedly high survival rates of 1 year (52.2%), 2 years (23.2%), and 3 years (11.6%), which were significantly higher than in patients not undergoing operation (n = 22).

摘要

由于主门静脉内的瘤栓出现在肝细胞癌(HCC)的终末期,人们认为任何手术切除瘤栓的尝试都是不切实际的,因为恶性肿瘤本身无法完全切除。在过去5年中,我们在298例HCC患者中的29例中进行了瘤栓切除术联合肝切除术。这种联合治疗最初是作为预防食管静脉曲张即将破裂的紧急措施而决定的,而不是为了提高患者的生存率。由于在去除血栓后获得了门静脉血流,这种情况使得能够进行经导管动脉栓塞术(TAE)和/或经皮乙醇注射治疗(PEIT)。虽然提高患者生存率不是急诊手术的主要目标,且手术死亡率为11%,但本系列中的其他患者中有一半的1年(52.2%)、2年(23.2%)和3年(11.6%)生存率意外地高,显著高于未接受手术的患者(n = 22)。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验